naphthalen-1-ylmethyl formate | 1136100-42-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: naphthalen-1-ylmethyl formate
• CAS: 1136100-42-9
• 化学式: C₁₂H₁₀O₂
• 分子量: 186.21
• InChiKey: BMROAZJUDKJHOY-UHFFFAOYSA-N

物化性质

• 沸点：
  321.8±11.0 °C(Predicted)
• 密度：
  1.163±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-甲氧基苯乙烯 、 naphthalen-1-ylmethyl formate 在 十二羰基三钌 、 N-dodecyl-2-hydroxymethylimidazole 作用下， 以 neat (no solvent) 为溶剂， 反应 24.0h， 生成 naphthalen-1-ylmethyl 3-(4-methoxyphenyl)propanoate 、 naphthalen-1-ylmethyl 2-(4-methoxyphenyl)propanoate
  参考文献：
  名称：

  Remarkable Improvement Achieved by Imidazole Derivatives in Ruthenium-Catalyzed Hydroesterification of Alkenes Using Formates

  摘要：

  Imidazole derivatives are revealed to be effective ligands in the Ru-catalyzed hydroesterification of alkenes using formates, affording one-carbon-elongated esters in high yields. Further, intramolecular hydroesterification was successfully performed to give lactones for the first time. Imidazole derivatives can contribute to promote the reaction as well as to suppress the undesired decarbonylation of formate. Toxic CO gas, a directing group, and large excess alkenes are not required.

  DOI：

  10.1021/ol301850y
• 作为产物：
  描述：

  甲酸 、 1-萘甲醇 反应 3.5h， 以32%的产率得到naphthalen-1-ylmethyl formate
  参考文献：
  名称：

  Remarkable Improvement Achieved by Imidazole Derivatives in Ruthenium-Catalyzed Hydroesterification of Alkenes Using Formates

  摘要：

  Imidazole derivatives are revealed to be effective ligands in the Ru-catalyzed hydroesterification of alkenes using formates, affording one-carbon-elongated esters in high yields. Further, intramolecular hydroesterification was successfully performed to give lactones for the first time. Imidazole derivatives can contribute to promote the reaction as well as to suppress the undesired decarbonylation of formate. Toxic CO gas, a directing group, and large excess alkenes are not required.

  DOI：

  10.1021/ol301850y

文献信息

• [EN] FUSED QUINOLINE DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ DE QUINOLINE FUSIONNÉE ET UTILISATION DE CELUI-CI
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005105802A1

  公开（公告）日：2005-11-10

  The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein Rl is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6 is (cyclic group optionally having substituent(s)) -carbonyl, and the like; R7, R8, R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and --- represents a single bond or a double bond, or a salt thereof, and the like.

  本发明旨在提供一种具有神经激肽2（NK2）受体拮抗作用的喹啉衍生物，并涉及一种由式（I）表示的化合物，其中R1是氢原子等；R2是氢原子，可选地具有取代基的碳氢基团等；R3是未取代的（即缺失），氢原子等；R4和R5相同或不同，每个是氢原子，可选地具有取代基的碳氢基团等；R6是（环状基团，可选地具有取代基）-羰基等；R7、R8、R9和R10相同或不同，每个是氢原子，卤素等；或R7和R8、R8和R9、以及R9和R10可以与相邻的碳原子一起形成环；n是1到5的整数；---表示未取代的（即缺失）或单键；---表示单键或双键，或其盐等。
• [EN] TUBULYSIN DERIVATIVES AND METHODS FOR PREPARING THE SAME<br/>[FR] DÉRIVÉS DE TUBULYSINE ET LEURS PROCÉDÉS DE PRÉPARATION
  申请人：UNIV GRONINGEN

  公开号：WO2020022892A1

  公开（公告）日：2020-01-30

  The invention relates to novel means and methods for the synthesis of tubulysin and derivatives thereof, which find their use e.g. as cytotoxic agents in targeted drug delivery. Provided is a method for preparing a tubulysin derivative, comprising reacting compounds A, B and C in a 3- component Passerini reaction, wherein compound A is a carboxylic acid according to the general formula (A); wherein compound B is an aldehyde according to the general formula (B); and wherein compound C is an isocyanide according to the general formula (C).

  该发明涉及一种用于合成管肽素及其衍生物的新手段和方法，这些管肽素及其衍生物可用作靶向药物传递中的细胞毒性剂。提供了一种制备管肽素衍生物的方法，包括在三组分Passerini反应中使化合物A、B和C反应，其中化合物A是符合通用式(A)的羧酸；化合物B是符合通用式(B)的醛；化合物C是符合通用式(C)的异氰酸酯。
• [EN] N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM<br/>[FR] INDOLES N-ARYLSULFONYL-3-SUBSTITUES PRESENTANT UNE AFFINITE POUR LE RECEPTEUR DE LA SEROTONINE, METHODE DE PREPARATION ET COMPOSITION PHARMACEUTIQUE CONTENANT CES INDOLES
  申请人：SUVEN LIFE SCIENCES LTD

  公开号：WO2004048330A1

  公开（公告）日：2004-06-10

  The present invention relates to novel N-arylsulfonyl-3-substituted indole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their geometric forms, their N-oxides, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel N-arylsulfonyl-3-substituted indoles of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, and pharmaceutically acceptable compositions containing them. This invention also relates to the process for preparing compounds of the general formula (I), pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine. This invention also relates to the novel intermediates involved therein and process of their preparation.

  本发明涉及新型的N-芳基亚磺酰基-3-取代吲哚化合物、其衍生物、类似物、互变异构体、立体异构体、几何异构体、N-氧化物、多晶型、药物可接受的盐、药物可接受的溶剂化物以及含有它们的药物可接受组合物。本发明特别涉及具有通用公式(I)的新型N-芳基亚磺酰基-3-取代吲哚、其衍生物、类似物、互变异构体、立体异构体、多晶型、药物可接受的盐、药物可接受的溶剂化物以及含有它们的药物可接受组合物。本发明还涉及制备通用公式(I)化合物的过程、含有此类化合物的药物组合物以及此类化合物和组合物在医学中的用途。本发明还涉及其中涉及的新中间体及其制备过程。
• [EN] ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C<br/>[FR] POLYTHÉRAPIE ANTICANCÉREUSE AVEC UN INHIBITEUR DE N-(1-ACRYLOYL-AZÉTIDIN-3-YL)-2-((1H-INDAZOL-3-YL) AMINO) MÉTHYL)-1 H-IMIDAZOLE-5-CARBOXAMIDE DE KRAS-G12C
  申请人：TAIHO PHARMACEUTICAL CO LTD

  公开号：WO2021215545A1

  公开（公告）日：2021-10-28

  A method of treating cancer comprises administering: (a) a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and (b) a therapeutically effective amount of an additional anti-cancer agent, to a subject in need of such treatment, the compound of Formula (I) being: where X, R1, R2, ring A, L1, L2, L3, and R5 are as defined in this disclosure.

  治疗癌症的方法包括向需要此类治疗的受试者施用：(a) 公式(I)的化合物或其药用可接受的盐的治疗有效量；和(b) 另一种抗癌药物的治疗有效量，其中公式(I)的化合物为：其中X、R1、R2、环A、L1、L2、L3和R5的定义如本公开说明书中所定义。
• NITROGEN-CONTAINING TRICYCLIC DERIVATIVE HAVING HIV REPLICATION INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP3305789A1

  公开（公告）日：2018-04-11

  The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: wherein A3 is CR3A, CR3A R3B, N or NR3C; R3A, R3B, R4A and R4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; R4 is a hydrogen atom or a carboxy protecting group.

  本发明提供了一种具有抗病毒活性的新型化合物，特别是具有抑制HIV复制活性的化合物和含有该化合物的药物。该化合物由以下式表示： 其中A3为CR3A、CR3A R3B、N或NR3C；R3A、R3B、R4A和R4B分别独立地为氢原子、卤素、氰基、取代或未取代的烷基、取代或未取代的炔基，或取代或未取代的非芳香碳环烷基；R3C为氢原子、取代或未取代的烷基，或取代或未取代的非芳香碳环烷基；环T1为取代或未取代的含氮非芳香杂环；R1为氢原子、卤素、氰基，或取代或未取代的烷基；R2分别为取代或未取代的烷基或类似物；n为1或2；R3为取代或未取代的芳香碳环烷基或类似物；R4为氢原子或羧基保护基。